GSK plc Form 6-K: Report of foreign private issuer
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2017-12-21: Form 6-K; Period of report 2017-12-21; Description FDA APPROVAL - ON ICS/LABA COMBINATIONS IN ASTHMA; Document a0533a.htm.
- 2017-12-18: Form 6-K; Period of report 2017-12-18; Description DIRECTOR/PDMR SHAREHOLDING; Document a6981z.htm.
- 2017-12-15: Form 6-K; Period of report 2017-12-15; Description TRANSFER OF SHARES OUT OF TREASURY; Document a4371z.htm.
- 2017-12-12: Form 6-K; Period of report 2017-12-12; Description DIRECTOR/PDMR SHAREHOLDING; Document a1412z.htm.
| Filed | Form | Period of report | Description | Document |
|---|---|---|---|---|
| 2017-12-21 | 6-K | 2017-12-21 | FDA APPROVAL - ON ICS/LABA COMBINATIONS IN ASTHMA | a0533a.htm |
| 2017-12-18 | 6-K | 2017-12-18 | DIRECTOR/PDMR SHAREHOLDING | a6981z.htm |
| 2017-12-15 | 6-K | 2017-12-15 | TRANSFER OF SHARES OUT OF TREASURY | a4371z.htm |
| 2017-12-12 | 6-K | 2017-12-12 | DIRECTOR/PDMR SHAREHOLDING | a1412z.htm |
| 2017-12-12 | 6-K | 2017-12-12 | GSK GAINS US APPROVAL FOR NUCALA TO TREAT EGPA | a1364z.htm |
| 2017-12-12 | 6-K | 2017-12-12 | PROMISING DATA FOR GSK2857916 AT ASH MEETING | a0231z.htm |
| 2017-12-06 | 6-K | 2017-12-06 | NEW DATA - SHINGRIX IN IMMUNE-COMPROMISED PATIENTS | a5244y.htm |
| 2017-12-01 | 6-K | 2017-12-01 | DIRECTOR/PDMR SHAREHOLDING | a1714y.htm |
| 2017-12-01 | 6-K | 2017-12-01 | DIRECTOR/PDMR SHAREHOLDING | a1706y.htm |
| 2017-12-01 | 6-K | 2017-12-01 | TOTAL VOTING RIGHTS | a1688y.htm |
| 2017-11-27 | 6-K | 2017-11-27 | VIIV STARTS PHASE 3 LONGACTING HIV TREATMENT STUDY | a6227x.htm |
| 2017-11-22 | 6-K | 2017-11-22 | VIIV JULUCA APPROVED IN US AS FIRST 2-DRUG REGIMEN | a1719x.htm |
| 2017-11-21 | 6-K | 2017-11-21 | GSK PUBLISHES 2018 DIVIDEND DATES | a1348x.htm |
| 2017-11-16 | 6-K | 2017-11-16 | TRELEGY ELLIPTA EU APPROVAL FOR TREATMENT OF COPD | a6797w.htm |
| 2017-11-13 | 6-K | 2017-11-13 | DIRECTOR/PDMR SHAREHOLDING | a2017w.htm |
| 2017-11-09 | 6-K | 2017-11-09 | BLOCK LISTING INTERIM REVIEW | a1027w.htm |
| 2017-11-08 | 6-K | 2017-11-08 | DIRECTORATE CHANGE | a9162v.htm |
| 2017-11-08 | 6-K | 2017-11-08 | DIRECTORATE CHANGE | a9107v.htm |
| 2017-11-07 | 6-K | 2017-11-07 | US REGULATORY APPLICATION FOR MEPOLIZUMAB IN COPD | a8270v.htm |
| 2017-11-02 | 6-K | 2017-11-02 | BCMA RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION | a3634v.htm |
| 2017-11-01 | 6-K | 2017-11-01 | TOTAL VOTING RIGHTS | a2716v.htm |
| 2017-11-01 | 6-K | 2017-11-01 | SUPERIORITY OF ANORO ELLIPTA DEMONSTRATED FOR COPD | a2599v.htm |
| 2017-10-25 | 6-K | 2017-10-25 | CDC ACIP MAKES RECOMMENDATIONS FOR USE OF SHINGRIX | a6410u.htm |
| 2017-10-25 | 6-K | 2017-10-25 | 3RD QUARTER RESULTS | a3qresults.htm |
| 2017-10-25 | 6-K | 2017-10-25 | DIRECTOR/PDMR SHAREHOLDING | a6232u.htm |
| 2017-10-23 | 6-K | 2017-10-23 | GSK S SHINGRIX RECEIVES US FDA APPROVAL | a2676u.htm |
| 2017-10-20 | 6-K | 2017-10-20 | DIRECTOR/PDMR SHAREHOLDING | a2494u.htm |
| 2017-10-20 | 6-K | 2017-10-20 | DIRECTOR/PDMR SHAREHOLDING | a2488u.htm |
| 2017-10-16 | 6-K | 2017-10-16 | DIRECTOR/PDMR SHAREHOLDING | a7390t.htm |
| 2017-10-16 | 6-K | 2017-10-16 | DIRECTOR/PDMR SHAREHOLDING | a7379t.htm |
| 2017-10-16 | 6-K | 2017-10-16 | DIRECTOR/PDMR SHAREHOLDING | a7383t.htm |
| 2017-10-16 | 6-K | 2017-10-16 | DIRECTOR/PDMR SHAREHOLDING | a7381t.htm |
| 2017-10-16 | 6-K | 2017-10-16 | DIRECTOR/PDMR SHAREHOLDING | a6957t.htm |
| 2017-10-16 | 6-K | 2017-10-16 | DIRECTOR/PDMR SHAREHOLDING | a6941t.htm |
| 2017-10-13 | 6-K | 2017-10-13 | GSK FIRST APPROVAL OF SHINGRIX IN CANADA | a6205t.htm |
| 2017-10-13 | 6-K | 2017-10-13 | DIRECTOR/PDMR SHAREHOLDING | a6109t.htm |
| 2017-10-13 | 6-K | 2017-10-13 | DIRECTOR/PDMR SHAREHOLDING | a6106t.htm |
| 2017-10-13 | 6-K | 2017-10-13 | DIRECTOR/PDMR SHAREHOLDING | a5815t.htm |
| 2017-10-11 | 6-K | 2017-10-11 | DIRECTOR/PDMR SHAREHOLDING | a3432t.htm |
| 2017-10-02 | 6-K | 2017-10-02 | TOTAL VOTING RIGHTS | a3998s.htm |
| 2017-09-25 | 6-K | 2017-09-25 | DIRECTOR/PDMR SHAREHOLDING | a7420r.htm |
| 2017-09-20 | 6-K | 2017-09-20 | POSITIVE IMPACT RESULTS FOR TRELEGY IN COPD | a2539r.htm |
| 2017-09-19 | 6-K | 2017-09-19 | TRELEGY ELLIPTA: FDA APPROVAL IN COPD RECEIVED | a0985r.htm |
| 2017-09-15 | 6-K | 2017-09-15 | TRELEGY ELLIPTA: POSITIVE OPINION FROM CHMP EUROPE | a8564q.htm |
| 2017-09-14 | 6-K | 2017-09-14 | UNANIMOUS FDA APPROVAL FOR SHINGRIX IN OVER 50S | a7264q.htm |
| 2017-09-12 | 6-K | 2017-09-12 | DIRECTOR/PDMR SHAREHOLDING | a5504q.htm |
| 2017-09-12 | 6-K | 2017-09-12 | GSK: PHASE III RESULTS ON MEPO IN COPD IN NEJM | a4754q.htm |
| 2017-09-11 | 6-K | 2017-09-11 | GSK ANNOUNCE POSITIVE RESULTS FROM SLS LUNG STUDY | a3378q.htm |
| 2017-09-06 | 6-K | 2017-09-06 | DIRECTOR/PDMR SHAREHOLDING | a0270q.htm |
| 2017-09-01 | 6-K | 2017-09-01 | TOTAL VOTING RIGHTS | a5734p.htm |
| 2017-08-10 | 6-K | 2017-08-10 | DIRECTOR/PDMR SHAREHOLDING | a7095n.htm |
| 2017-08-10 | 6-K | 2017-08-10 | DIRECTOR/PDMR SHAREHOLDING | a6532n.htm |
| 2017-08-04 | 6-K | 2017-08-04 | BASE PROSPECTUS RE GBP15BN EMTN PROGRAMME | a1341n.htm |
| 2017-08-01 | 6-K | 2017-08-01 | TOTAL VOTING RIGHTS | a7426m.htm |
| 2017-07-28 | 6-K | 2017-07-28 | DIRECTOR/PDMR SHAREHOLDING | a4870m.htm |
| 2017-07-28 | 6-K | 2017-07-28 | DIRECTOR/PDMR SHAREHOLDING | a4854m.htm |
| 2017-07-26 | 6-K | 2017-07-26 | HALF-YEAR REPORT | a1411m.htm |
| 2017-07-26 | 6-K | 2017-07-26 | DIRECTOR/PDMR SHAREHOLDING | a1733m.htm |
| 2017-07-26 | 6-K/A | 2017-07-26 | DIRECTOR/PDMR SHAREHOLDING - REPLACEMENT | a1708m-replacement.htm |
| 2017-07-25 | 6-K | 2017-07-25 | VIIV ANNOUNCES RESULTS FROM NEAT 022 STUDY | a0442m.htm |
| 2017-07-25 | 6-K | 2017-07-25 | VIIV ANNOUNCES POSITIVE RESULTS FROM DAWNING | a0437m.htm |
| 2017-07-24 | 6-K | 2017-07-24 | LATTE-2 PHII RESULTS PRESENTED AT IAS IN PARIS | a8685l.htm |
| 2017-07-21 | 6-K | 2017-07-21 | DIRECTOR/PDMR SHAREHOLDING | a8000l.htm |
| 2017-07-21 | 6-K | 2017-07-21 | DIRECTOR/PDMR SHAREHOLDING | a7994l.htm |
| 2017-07-21 | 6-K | 2017-07-21 | GSK SUBMITS EU FILING FOR RELVAR ELLIPTA EXTENSION | a7860l.htm |
| 2017-07-21 | 6-K | 2017-07-21 | DIRECTORATE CHANGE | a7565l.htm |
| 2017-07-17 | 6-K | 2017-07-17 | DIRECTOR/PDMR SHAREHOLDING | a3051l.htm |
| 2017-07-17 | 6-K | 2017-07-17 | DIRECTOR/PDMR SHAREHOLDING | a3051l.htm |
| 2017-07-17 | 6-K | 2017-07-17 | DIRECTOR/PDMR SHAREHOLDING | a3036l.htm |
| 2017-07-17 | 6-K | 2017-07-17 | DIRECTOR/PDMR SHAREHOLDING | a3013l.htm |
| 2017-07-17 | 6-K | 2017-07-17 | DIRECTOR/PDMR SHAREHOLDING | a2963l.htm |
| 2017-07-17 | 6-K | 2017-07-17 | DIRECTOR/PDMR SHAREHOLDING | a2935l.htm |
| 2017-07-17 | 6-K | 2017-07-17 | DIRECTOR/PDMR SHAREHOLDING | a2767l.htm |
| 2017-07-14 | 6-K | 2017-07-14 | DIRECTOR/PDMR SHAREHOLDING | a1721l.htm |
| 2017-07-14 | 6-K | 2017-07-14 | DIRECTOR/PDMR SHAREHOLDING | a1705l.htm |
| 2017-07-14 | 6-K | 2017-07-14 | DIRECTOR/PDMR SHAREHOLDING | a1659l.htm |
| 2017-07-14 | 6-K | 2017-07-14 | DIRECTOR/PDMR SHAREHOLDING | a1364l.htm |
| 2017-07-12 | 6-K | 2017-07-12 | DIRECTOR/PDMR SHAREHOLDING | a9075k.htm |
| 2017-07-03 | 6-K | 2017-07-03 | TOTAL VOTING RIGHTS | a9078j.htm |
| 2017-06-28 | 6-K | 2017-06-28 | GSK ANNOUNCES US FILING FOR MEPO IN EGPA | a4772j.htm |
| 2017-06-27 | 6-K | 2017-06-27 | GSK STARTS PHIII STUDY ON MEPO FOR NASAL POLYPS | a2885j.htm |
| 2017-06-21 | 6-K | 2017-06-21 | DIRECTOR/PDMR SHAREHOLDING | a7870i.htm |
| 2017-06-21 | 6-K | 2017-06-21 | GSK PRESENTS SHINGRIX PHIII STUDY RESULTS AT ACIP | a7790i.htm |
| 2017-06-19 | 6-K | 2017-06-19 | GSK CONFIRMS START DATE FOR LUKE MIELS | a5169i.htm |
| 2017-06-12 | 6-K | 2017-06-12 | DIRECTOR/PDMR SHAREHOLDING | a8603h.htm |
| 2017-06-05 | 6-K | 2017-06-05 | DIRECTOR/PDMR SHAREHOLDING | a1944h.htm |
| 2017-06-02 | 6-K | 2017-06-02 | VIIV SUBMITS FIRST 2-DRUG HIV REGIMEN APPLICATION | a9373g.htm |
| 2017-06-01 | 6-K | 2017-06-01 | TOTAL VOTING RIGHTS | a8603g.htm |
| 2017-05-31 | 6-K | 2017-05-31 | DIRECTOR/PDMR SHAREHOLDING | a7503g.htm |
| 2017-05-22 | 6-K | 2017-05-22 | DIRECTOR/PDMR SHAREHOLDING | a8846f.htm |
| 2017-05-22 | 6-K | 2017-05-22 | DIRECTOR/PDMR SHAREHOLDING | a8833f.htm |
| 2017-05-22 | 6-K | 2017-05-22 | PH3 MUSCA STUDY PRESENTED AT ATS | a8605f.htm |
| 2017-05-18 | 6-K | 2017-05-17 | NEJM PUBLICATION OF PH3 STUDY INTO MEPO IN EGPA | a4845f.htm |
| 2017-05-12 | 6-K | 2017-05-12 | BLOCK LISTING INTERIM REVIEW | a0522f.htm |
| 2017-05-11 | 6-K | 2017-05-11 | DIRECTOR/PDMR SHAREHOLDING | a9327e.htm |
| 2017-05-10 | 6-K | 2017-05-10 | HEADLINE PHASE III RESULTS: MEPO IN COPD | a7779e.htm |
| 2017-05-04 | 6-K | 2017-05-04 | RESULT OF AGM | a2577e.htm |
| 2017-05-02 | 6-K | 2017-05-02 | DIRECTOR/PDMR SHAREHOLDING | a9183d.htm |
| 2017-05-02 | 6-K | 2017-05-02 | TOTAL VOTING RIGHTS | a8788d.htm |
| 2017-04-27 | 6-K | 2017-04-27 | DIRECTOR/PDMR SHAREHOLDING | a6180d.htm |